Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 3/20 | 0.35 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867699 | 1.00 | CYP1A2 (0.39) | CYP1A2ADH1ASHBGADH1CCA1 | |
| SCHEMBL868694 | 1.00 | CYP1A2 (0.39) | CYP1A2ADH1ASHBGADH1CCA1 | |
| SCHEMBL130310 | 1.00 | CYP1A2 (0.39) | CYP1A2ADH1ASHBGADH1CCA1 | |
| SCHEMBL868579 | 1.00 | CYP1A2 (0.39) | CYP1A2ADH1ASHBGADH1CCA1 | |
| SCHEMBL4717621 | 1.00 | CYP1A2 (0.39) | CYP1A2ADH1ASHBGADH1CCA1 | |
| SCHEMBL22523 | 0.97 | — | — | |
| SCHEMBL866488 | 0.92 | — | — | |
| SCHEMBL1482415 | 0.87 | CYP1A2 (0.44) | CYP1A2ADH1ASHBGTSHRALDH1A1 | |
| SCHEMBL1482398 | 0.87 | CYP1A2 (0.44) | CYP1A2ADH1ASHBGTSHRALDH1A1 | |
| SCHEMBL891565 | 0.87 | CYP1A2 (0.44) | CYP1A2ADH1ASHBGTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108422-A1 | Antifungal 1,2,4-triazolyl Derivatives | BASF SE (DE) | 2012-05-03 | — | — | US | disclosed |
| EP-2443098-A1 | ANTIFUNGAL 1, 2, 4-TRIAZOLYL DERIVATIVES | BASF SE (DE) | 2012-04-25 | — | — | EP | disclosed |
| EP-2443099-A1 | ANTIFUNGAL 1, 2, 4-TRIAZOLYL DERIVATIVES HAVING A 5- SULFUR SUBSTITUENT | BASF SE (DE) | 2012-04-25 | — | — | EP | disclosed |
| EP-2443097-A1 | ANTIFUNGAL 1, 2, 4-TRIAZOLYL DERIVATIVES | BASF SE (DE) | 2012-04-25 | — | — | EP | disclosed |
| EP-2443109-A1 | TRIAZOLE COMPOUNDS CARRYING A SULFUR SUBSTITUENT | BASF SE (DE) | 2012-04-25 | — | — | EP | disclosed |
| EP-2440535-A1 | ANTIFUNGAL 1,2,4-TRIAZOLYL DERIVATIVES HAVING A 5- SULFUR SUBSTITUENT | BASF SE (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-20120088660-A1 | Antifungal 1,2,4-triazolyl Derivatives | BASF SE (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20120088664-A1 | Antifungal 1,2,4-triazolyl derivatives having a 5-sulfur subtituent | BASF SE (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20120088663-A1 | Triazole Compounds Carrying a Sulfur Substituent | BASF SE (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20120077676-A1 | Antifungal 1,2,4-Triazolyl Derivatives Having a 5-Sulfur Substituent | BASF SE (DE) | 2012-03-29 | — | — | US | disclosed |
| WO-2010142779-A1 | ANTIFUNGAL 1,2,4-TRIAZOLYL DERIVATIVES HAVING A 5- SULFUR SUBSTITUENT | BASF SE (DE) | 2010-12-16 | — | — | WO | disclosed |
| US-20100204320-A1 | PHARMACEUTICALS FOR XEROSIS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-12 | — | — | US | disclosed |
| US-7737182-B2 | Pharmaceuticals for xerosis | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-7718701-B2 | Prostaglandin, e.g., 1R,2R,3R,5R)-5-halo-2-[(1E,3S)-3-cycloalkyl-3-hydroxy-1-propenyl]-3-hydroxycyclopentyl]-(5Z)-5-alkenoic acids; treating in particular, symptoms of atopic dermatitis | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| EP-1527781-B1 | ANTIPRURITIC AGENT | TAISHO PHARMACEUTICAL CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-20050192357-A1 | Pharmaceuticals for xerosis | Sato, Fumie | 2005-09-01 | — | — | US | disclosed |
| EP-1527781-A1 | ANTIPRURITIC AGENT | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
| US-20050009917-A1 | Antipruritic agent | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009917-A1 | Antipruritic agent | HRH2, HRH4, HRH1 | CYP1A2 1723/4885ADH1A 873/4885SHBG 1221/4885 |
| US-20120088660-A1 | Antifungal 1,2,4-triazolyl Derivatives | ERG28, CYP51A1, DPM1 | CYP1A2 26/4885ADH1A 4065/4885SHBG 4451/4885 |
| US-20120088664-A1 | Antifungal 1,2,4-triazolyl derivatives having a 5-sulfur subtituent | STS, TST, ERG28 | CYP1A2 85/4885ADH1A 3849/4885SHBG 4114/4885 |
| US-20120088663-A1 | Triazole Compounds Carrying a Sulfur Substituent | TST, STS, SQOR | CYP1A2 37/4885ADH1A 3799/4885SHBG 3237/4885 |
| US-20120108422-A1 | Antifungal 1,2,4-triazolyl Derivatives | ERG28, CYP51A1, DPM1 | CYP1A2 26/4885ADH1A 4065/4885SHBG 4451/4885 |
| US-20120077676-A1 | Antifungal 1,2,4-Triazolyl Derivatives Having a 5-Sulfur Substituent | ERG28, STS, CYP51A1 | CYP1A2 44/4885ADH1A 3851/4885SHBG 4352/4885 |
| US-20100204320-A1 | PHARMACEUTICALS FOR XEROSIS | PTGDR, PTGDR2, PTGIR | CYP1A2 899/4885ADH1A 511/4885SHBG 657/4885 |
| US-20050192357-A1 | Pharmaceuticals for xerosis | PTGDR, PTGDR2, PTGIR | CYP1A2 993/4885ADH1A 386/4885SHBG 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.